Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing

Published: Friday, May 24, 2013
Last Updated: Friday, May 24, 2013
Bookmark and Share
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.

Aptiv Solutions announces publication of a Tufts Center for the Study of Drug Development (CSDD) report on the adoption and impact of adaptive trial designs.

Adaptive designs allow pre-planned modifications to clinical trials, such as terminating studies early to spare patients from ineffective drugs or adding patients to help ensure the trial will return a statistically significant result.

Approximately 20% of clinical trials currently underway already use adaptive designs, according to Tufts CSDD’s research. The study indicates adoption should increase significantly in the next few years, particularly for exploratory phase trials. In a session previewing the report, the majority of forty executives from top pharmaceutical companies agreed that futility analysis should become standard practice in all phase II and III studies. Data indicates widespread use of simple adaptive designs, such as early study terminations due to futility and sample size re-estimation, could save sponsor organizations $100 to $200 million annually.

“The industry is investing heavily in improving clinical trial quality and efficiency and now years of evidence has made the promise of adaptive designs clear. Yet, barriers remain to this approach reaching its full potential to protect patients and free R&D dollars for more therapies and devices,” says Pat Donnelly, Chairman and Chief Executive Officer of Aptiv Solutions.

“An important finding of our study was that a primary factor limiting adoption of adaptive designs is internal organizational resistance, not lack of support from regulatory agencies. Study participants believe that internal functions, for example regulatory affairs, are risk-averse and prefer more clarity from regulatory agencies. Regulatory agencies, on the other hand, have provided guidance, and appear to be receptive to exploratory phase adaptive trial designs,” says Ken Getz, Director of Sponsored Research at Tufts CSDD.

“Adaptive trials allow study sponsors to react to data acquired during an investigation and make adjustments, improving the utility of information the studies provide to patients, doctors, regulators, and sponsors. It’s like crossing the road with your eyes open. The time is right for sponsor companies to expand their use of adaptive designs” says Donnelly.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Aptiv Solutions Growing: Opens New Office in North Carolina
New office is located at 4505 Emperor Boulevard in the Imperial Center.
Monday, December 10, 2012
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!